|
|
News Breaks | | | | October 3, 2012 | | 14:44 EDT |  | ALR | Alere rallies after disclosing deal with FDA, updating revenue view
Alere (ALR) is surging after the company disclosed earlier today that it had reached a deal with the FDA on final release specifications for its Alere Triage meter-based products. The new specifications will further align the product release specifications to the package insert, and, as expected, represents a further tightening of the release specifications for Alere's Triage products, the company said. The company believes that the new specifications will result in lower manufacturing yields, but it continued to expand its manufacturing capacity to address the expected lower yield rate. Alere announced that revenue from its Alere Triage Cardiac Panel products in the U.S. were about $6M in the third quarter, in-line with its previous guidance of $4M-$8M. The company projects a supply shortfall for its Cardiac Panel products during October but expects to be able to meet demand for its cardiac panel in the U.S. from November onwards, it said. Alere estimates that its revenue from the panels in the U.S. will be about $6M-$8M in the fourth quarter. Revenues from sales of the TOX product line in the U.S. came in at $7M for the third quarter of 2012. Alere expects revenue of approximately $4M-$5M from U.S. sales of the product in the fourth quarter. In mid-afternoon trading, Alere rose $1.60, or 8.25%, to $20.99. | |
|
News For ALR From The Last 14 Days Check below for free stories on ALR the last two weeks. |
|
|
| May 21, 2013 | | 10:12 EDT |  | ALR | Alere pressured by Coppersmith to explore sale of testing unit, Reuters says
 Subscribe for More Information | | | 09:59 EDT | | ALR | Investor wants Alere to sell toxicology drug testing business, Reuters says
According to unnamed sources, the activist investor estimates the unit sale could fetch as much as $2.5B. | | | May 14, 2013 | | 10:01 EDT |  | ALR | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AVG Technologies (AVG) downgraded to Neutral from Buy at Goldman... Cigna (CI) downgraded to Hold from Buy at Jefferies... Cree (CREE) downgraded to Neutral from Buy at Sterne Agee... Melco Crown (MPEL) downgraded to Neutral from Buy at UBS... SolarCity (SCTY) downgraded to Neutral from Buy at Roth Capital... KB Home (KBH) downgraded to Market Perform from Outperform at Raymond James... Ryland Group (RYL) downgraded to Underperform from Market Perform at Raymond James... Alere (ALR) downgraded to Hold from Buy at Craig-Hallum... Evolution Petroleum (EPM) downgraded to Hold from Buy at MLV Equity... Oil States (OIS) downgraded to Hold from Buy at BB&T... VIVUS (VVUS) downgraded to Neutral from Buy at Lazard Capital. | | | 07:55 EDT | | ALR | Alere downgraded to Hold from Buy at Craig-Hallum
Subscribe for More Information | | | May 9, 2013 | | 07:33 EDT |  | ALR | Alere reports Q1 adjusted EPS 53c, consensus 51c
Reports Q1 revenue $739.2M, consensus $727.66M | | | 06:08 EDT | | ALR | Coppersmith Capital reports 3.6% stake in Alere, sends letter
Coppersmith Capital said it delivered a letter to Alere's CEO Ronald Zwanziger, "expressing strong disappointment at the management and Board’s failure to address the numerous issues facing Alere or engage in a constructive dialogue with Coppersmith regarding the clear and compelling need for change in the composition of the Board." | | | May 8, 2013 | | 17:00 EDT | | ALR | Coppersmith Capital nominates three to Alere board
Subscribe for More Information | |
|
|
|
|
|
|
